Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
about
P1343
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contraClinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastasesTargeting molecular resistance in castration-resistant prostate cancerQuo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesEmerging data on androgen receptor splice variants in prostate cancerAddressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trialsComparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer.Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agentsPIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain.Treatment sequencing in metastatic castrate-resistant prostate cancerAdvanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.The evolution of prostate cancer therapy: targeting the androgen receptorPharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.Advances in systemic therapies for metastatic castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer: time for innovation.Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.Novel agents for castration-resistant prostate cancer: Early experience and beyond.The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS).Loss of SLCO1B3 drives taxane resistance in prostate cancerCritical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.Progress in the mechanism and drug development of castration-resistant prostate cancer.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.
P2860
Q24289204-D1447706-D483-43EA-8EBB-3BE5C92915B4Q26744355-22BB4323-B375-4534-8DED-2C31866E3835Q26795445-902861D1-A98F-4396-ACAB-255821C17448Q27011642-2F105677-3A72-4AB2-854B-62AAEE603486Q28077830-CAAE4291-B43C-407A-9C78-2256A741AC39Q30244818-A26D8935-AD9D-4F21-BF33-2BB1DD2B8D93Q33581903-CFF5C401-5082-4891-B6A7-91AAB8BD425FQ33621403-B05621AF-0874-4CF0-9ED6-D842A3C24832Q33775723-B7826E6B-BB82-4A89-BCF9-1D3A74CC87DDQ34250350-0FF2C64A-10C9-4A2D-861A-D6C32341A1A9Q35099127-1DE30437-773B-4191-BB7E-304295FBECF6Q35358010-790C962C-F58A-4AFA-A6FC-138C259CDD97Q35602518-CFA7ECE1-6C75-4C74-A3A0-C8532174214DQ35740095-194AEE8B-E195-4756-8B3D-36094A1BCE28Q35809973-60418136-06EE-438B-B703-8774B7B8FC35Q35875775-A884F1D0-57F1-4AD4-B1AC-0948B6811FC7Q35932706-9396956E-D64B-40CE-B15A-0F2AB714420EQ35965406-0783D939-D7B1-4A5D-88C2-7581364CEE97Q36389442-1AD7A2DE-4DF8-41EF-BC40-0451D5945A99Q36414184-06066AF6-6440-404B-A0EA-A01EEC8D7B92Q36896806-4B69A404-A458-4242-881F-9BF8C8663885Q37691775-C6A8979B-85CA-4539-9F55-EB8F2AEFD93FQ38199939-45CC7EF8-F13C-4AC9-AAC5-3C132A5EC310Q38244522-940BF412-B697-4582-A427-887B01A5D840Q38266909-65D47F67-4B26-47D1-8C39-C12AA2A08323Q38267175-C65C5212-9D7C-4280-B708-A42EBA16514BQ38282461-5E664070-8096-4FC3-ACF8-04D95EDB11A7Q38312041-B1F68613-2151-4843-81AF-F0872A7189EFQ38389933-4CEC31BF-B776-4409-82CA-B2DF790D7E7FQ38541877-D331F887-0423-4369-A46B-6C4F51C9FA61Q38574684-FE1C728E-F2D2-40AB-A55F-5036CCD47808Q38575004-07AD50BF-2887-4F5D-8CC7-0248CB803398Q38587547-B99C33F5-01F8-4D4F-A8E8-C82CE7652270Q38744269-3E403A49-1860-4DF9-9AD4-807309DEF4F3Q38751260-8FCEA7BC-397A-4F40-BA51-62B0DF1A4E69Q38754074-815140BE-A5BD-4484-A46C-969A49977E17Q38826609-75730EEA-E09A-4A80-B4C1-DD0920978226Q38865487-0CAC80DC-D2AB-42C6-AA2E-2EAFD7120BB7Q38893354-236AD4D5-6433-4F5A-8FF7-41923D734A56Q39016544-8D90AA36-E264-4CA3-9875-CB73EEBE8E2B
P2860
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@en
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@nl
type
label
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@en
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@nl
prefLabel
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@en
Cross-resistance between taxan ...... ion-resistant prostate cancer.
@nl
P2093
P50
P1476
Cross-resistance between taxan ...... tion-resistant prostate cancer
@en
P2093
E S de Morrée
R H J Mathijssen
W M van Weerden
P304
P356
10.1016/J.EJCA.2013.09.026
P4510
P577
2013-10-24T00:00:00Z